The tangential field-in-field (FIF) technique is a widely used method in breast radiation therapy, known for its efficiency and the reduced number of fields required in treatment planning. However, it is labor-intensive, requiring manual shaping of the multileaf collimator (MLC) to minimize hot spots. This study aims to develop a novel automated FIF planning approach for tangential breast radiation therapy using Digitally Reconstructed Radiograph (DRR) images. A total of 78 patients were selected to train and test a fluence map prediction model based on U-Net architecture. DRR images were used as input data to predict the fluence maps. The predicted fluence maps for each treatment plan were then converted into MLC positions and exported as Digital Imaging and Communications in Medicine (DICOM) files. These files were used to recalculate the dose distribution and assess dosimetric parameters for both the PTV and OARs. The mean absolute error (MAE) between the predicted and original fluence map was 0.007 ± 0.002. The result of gamma analysis indicates strong agreement between the predicted and original fluence maps, with gamma passing rate values of 95.47 ± 4.27 for the 3 %/3 mm criteria, 94.65 ± 4.32 for the 3 %/2 mm criteria, and 83.4 ± 12.14 for the 2 %/2 mm criteria. The plan quality, in terms of tumor coverage and doses to organs at risk (OARs), showed no significant differences between the automated FIF and original plans. The automated plans yielded promising results, with plan quality comparable to the original.

To develop a multiparametric breast MRI radiomics and deep learning-based multimodal model for predicting preoperative Ki-67 expression status in breast cancer, with the potential to advance individualized treatment and precision medicine for breast cancer patients. We included 176 invasive breast cancer patients who underwent breast MRI and had Ki-67 results. The dataset was randomly split into training (70 %) and test (30 %) sets. Features from T1-weighted imaging (T1WI), diffusion-weighted imaging (DWI), T2-weighted imaging (T2WI), and dynamic contrast-enhanced MRI (DCE-MRI) were fused. Separate models were created for each sequence: T1, DWI, T2, and DCE. A multiparametric MRI (mp-MRI) model was then developed by combining features from all sequences. Models were trained using five-fold cross-validation and evaluated on the test set with receiver operating characteristic (ROC) curve area under the curve (AUC), accuracy, sensitivity, specificity, positive predictive value, negative predictive value, and F1 score. Delong's test compared the mp-MRI model with the other models, with P < 0.05 indicating statistical significance. All five models demonstrated good performance, with AUCs of 0.83 for the T1 model, 0.85 for the DWI model, 0.90 for the T2 model, 0.92 for the DCE model, and 0.96 for the mp-MRI model. Delong's test indicated statistically significant differences between the mp-MRI model and the other four models, with P values < 0.05. The multiparametric breast MRI radiomics and deep learning-based multimodal model performs well in predicting preoperative Ki-67 expression status in breast cancer.

Breast cancer is the most frequently diagnosed human cancer in the United States at present. Early detection is crucial for its successful treatment. X-ray mammography and digital breast tomosynthesis are currently the main methods for breast cancer screening. However, both have known limitations in terms of their sensitivity and specificity to breast cancers, while also frequently causing patient discomfort due to the requirement for breast compression. Breast computed tomography is a promising alternative, however, to obtain high-quality images, the X-ray dose needs to be sufficiently high. As the breast is highly radiosensitive, dose reduction is particularly important. Phase-contrast computed tomography (PCT) has been shown to produce higher-quality images at lower doses and has no need for breast compression. It is demonstrated in the present study that, when imaging full fresh mastectomy samples with PCT, deep learning-based image denoising can further reduce the radiation dose by a factor of 16 or more, without any loss of image quality. The image quality has been assessed both in terms of objective metrics, such as spatial resolution and contrast-to-noise ratio, as well as in an observer study by experienced medical imaging specialists and radiologists. This work was carried out in preparation for live patient PCT breast cancer imaging, initially at specialized synchrotron facilities.

The aim of this study was to develop and validate a machine learning (ML) based prediction model for sentinel lymph node metastasis in breast cancer to identify patients with a high risk of sentinel lymph node metastasis. In this machine learning study, we retrospectively collected 225 female breast cancer patients who underwent sentinel lymph node biopsy (SLNB). Feature screening was performed using the logistic regression analysis. Subsequently, five ML algorithms, namely LOGIT, LASSO, XGBOOST, RANDOM FOREST model and GBM model were employed to train and develop an ML model. In addition, model interpretation was performed by the Shapley Additive Explanations (SHAP) analysis to clarify the importance of each feature of the model and its decision basis. Combined univariate and multivariate logistic regression analysis, identified Multifocal, LVI, Maximum Diameter, Shape US, Maximum Cortical Thickness as significant predictors. We than successfully leveraged machine learning algorithms, particularly the RANDOM FOREST model, to develop a predictive model for sentinel lymph node metastasis in breast cancer. Finally, the SHAP method identified Maximum Diameter and Maximum Cortical Thickness as the primary decision factors influencing the ML model's predictions. With the integration of pathological and imaging characteristics, ML algorithm can accurately predict sentinel lymph node metastasis in breast cancer patients. The RANDOM FOREST model showed ideal performance. With the incorporation of these models in the clinic, can helpful for clinicians to identify patients at risk of sentinel lymph node metastasis of breast cancer and make more reasonable treatment decisions.

Accurate preoperative assessment of axillary lymph node metastasis (ALNM) in breast cancer is crucial for guiding treatment decisions. This study aimed to develop a deep-learning radiomics model for assessing ALNM and to evaluate its impact on radiologists' diagnostic accuracy. This multicenter study included 866 breast cancer patients from 6 hospitals. The data were categorized into training, internal test, external test, and prospective test sets. Deep learning and handcrafted radiomics features were extracted from ultrasound images of primary tumors and lymph nodes. The tumor score and LN score were calculated following feature selection, and a clinical-radiomics model was constructed based on these scores along with clinical-ultrasonic risk factors. The model's performance was validated across the 3 test sets. Additionally, the diagnostic performance of radiologists, with and without model assistance, was evaluated. The clinical-radiomics model demonstrated robust discrimination with AUCs of 0.94, 0.92, 0.91, and 0.95 in the training, internal test, external test, and prospective test sets, respectively. It surpassed the clinical model and single score in all sets (P < .05). Decision curve analysis and clinical impact curves validated the clinical utility of the clinical-radiomics model. Moreover, the model significantly improved radiologists' diagnostic accuracy, with AUCs increasing from 0.71 to 0.82 for the junior radiologist and from 0.75 to 0.85 for the senior radiologist. The clinical-radiomics model effectively predicts ALNM in breast cancer patients using noninvasive ultrasound features. Additionally, it enhances radiologists' diagnostic accuracy, potentially optimizing resource allocation in breast cancer management.

Phyllodes tumors (PTs) are rare breast tumors with high recurrence rates, current methods relying on post-resection pathology often delay detection and require further surgery. We propose a deep-learning-based Phyllodes Tumors Hierarchical Diagnosis Model (PTs-HDM) for preoperative identification and grading. Ultrasound images from five hospitals were retrospectively collected, with all patients having undergone surgical pathological confirmation of either PTs or fibroadenomas (FAs). PTs-HDM follows a two-stage classification: first distinguishing PTs from FAs, then grading PTs into benign or borderline/malignant. Model performance metrics including AUC and accuracy were quantitatively evaluated. A comparative analysis was conducted between the algorithm's diagnostic capabilities and those of radiologists with varying clinical experience within an external validation cohort. Through the provision of PTs-HDM's automated classification outputs and associated thermal activation mapping guidance, we systematically assessed the enhancement in radiologists' diagnostic concordance and classification accuracy. A total of 712 patients were included. On the external test set, PTs-HDM achieved an AUC of 0.883, accuracy of 87.3% for PT vs. FA classification. Subgroup analysis showed high accuracy for tumors < 2 cm (90.9%). In hierarchical classification, the model obtained an AUC of 0.856 and accuracy of 80.9%. Radiologists' performance improved with PTs-HDM assistance, with binary classification accuracy increasing from 82.7%, 67.7%, and 64.2-87.6%, 76.6%, and 82.1% for senior, attending, and resident radiologists, respectively. Their hierarchical classification AUCs improved from 0.566 to 0.827 to 0.725-0.837. PTs-HDM also enhanced inter-radiologist consistency, increasing Kappa values from - 0.05 to 0.41 to 0.12 to 0.65, and the intraclass correlation coefficient from 0.19 to 0.45. PTs-HDM shows strong diagnostic performance, especially for small lesions, and improves radiologists' accuracy across all experience levels, bridging diagnostic gaps and providing reliable support for PTs' hierarchical diagnosis.

Timely intervention and improved prognosis for breast cancer patients rely on early metastasis risk detection and accurate treatment predictions. This study introduces an advanced multimodal MRI and AI-driven 3D deep learning model, termed the 3D-MMR-model, designed to predict recurrence risk in non-metastatic breast cancer patients. We conducted a multicenter study involving 1199 non-metastatic breast cancer patients from four institutions in China, with comprehensive MRI and clinical data retrospectively collected. Our model employed multimodal-data fusion, utilizing contrast-enhanced T1-weighted imaging (T1 + C) and T2-weighted imaging (T2WI) volumes, processed through a modified 3D-UNet for tumor segmentation and a DenseNet121-based architecture for disease-free survival (DFS) prediction. Additionally, we performed RNA-seq analysis to delve further into the relationship between concentrated hotspots within the tumor region and the tumor microenvironment. The 3D-MR-model demonstrated superior predictive performance, with time-dependent ROC analysis yielding AUC values of 0.90, 0.89, and 0.88 for 2-, 3-, and 4-year DFS predictions, respectively, in the training cohort. External validation cohorts corroborated these findings, highlighting the model's robustness across diverse clinical settings. Integration of clinicopathological features further enhanced the model's accuracy, with a multimodal approach significantly improving risk stratification and decision-making in clinical practice. Visualization techniques provided insights into the decision-making process, correlating predictions with tumor microenvironment characteristics. In summary, the 3D-MMR-model represents a significant advancement in breast cancer prognosis, combining cutting-edge AI technology with multimodal imaging to deliver precise and clinically relevant predictions of recurrence risk. This innovative approach holds promise for enhancing patient outcomes and guiding individualized treatment plans in breast cancer care.

Breast cancer has remained one of the most frequent and life-threatening cancers in females globally, putting emphasis on better diagnostics in its early stages to solve the problem of therapy effectiveness and survival. This work enhances the assessment of breast cancer by employing progressive residual networks (PRN) and ResNet-50 within the framework of Progressive Residual Multi-Class Support Vector Machine-Net. Built on concepts of deep learning, this creative integration optimizes feature extraction and raises the bar for classification effectiveness, earning an almost perfect 99.63% on our tests. These findings indicate that PRMS-Net can serve as an efficient and reliable diagnostic tool for early breast cancer detection, aiding radiologists in improving diagnostic accuracy and reducing false positives. The separation of the data into different segments is possible to determine the architecture's reliability using the fivefold cross-validation approach. The total variability of precision, recall, and F1 scores clearly depicted in the box plot also endorse the competency of the model for marking proper sensitivity and specificity-highly required for combating false positive and false negative cases in real clinical practice. The evaluation of error distribution strengthens the model's rationale by giving validation of practical application in medical contexts of image processing. The high levels of feature extraction sensitivity together with highly sophisticated classification methods make PRMS-Net a powerful tool that can be used in improving the early detection of breast cancer and subsequent patient prognosis.

Achieving efficient analysis of multiple pathological indicators has great significance for breast cancer prognosis and therapeutic decision-making. In this study, we aim to explore a deep multi-task learning (MTL) framework for collaborative prediction of histological grade and proliferation marker (Ki-67) status in breast cancer using multi-phase dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). In the novel design of hybrid multi-task architecture (HMT-Net), co-representative features are explicitly distilled using a feature extraction backbone. A customized prediction network is then introduced to perform soft-parameter sharing between two correlated tasks. Specifically, task-common and task-specific knowledge is transmitted into tower layers for informative interactions. Furthermore, low-level feature maps containing tumor edges and texture details are recaptured by a hard-parameter sharing branch, which are then incorporated into the tower layer for each subtask. Finally, the probabilities of two histological indicators, predicted in the multi-phase DCE-MRI, are separately fused using a decision-level fusion strategy. Experimental results demonstrate that the proposed HMT-Net achieves optimal discriminative performance over other recent MTL architectures and deep models based on single image series, with the area under the receiver operating characteristic curve of 0.908 for tumor grade and 0.694 for Ki-67 status. Benefiting from the innovative HMT-Net, our proposed method elucidates its strong robustness and flexibility in the collaborative prediction task of breast biomarkers. Multi-phase DCE-MRI is expected to contribute valuable dynamic information for breast cancer pathological assessment in a non-invasive manner.